# 2026-23366: Adult Vitamin Injections Get Generic Green Light From FDA

2026-23366, Determination That M.V.I. ADULT (Multiple Vitamins for Injection) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-11-17; PRIA reads it as touching household money (as of 2026-11-17).

- Canonical: https://policyrisk.com/federal-register/2026-23366
- As of: 2026-11-17
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-23366
- Title: Determination That M.V.I. ADULT (Multiple Vitamins for Injection) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 73758
- Published: 2026-11-17
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-17

## In one line

Adult Vitamin Injections Get Generic Green Light From FDA

## Summary

The FDA has decided that M.V.I. ADULT vitamins for injection weren’t taken off the market because they were unsafe or ineffective. This means drug companies can now apply to make generic versions of these vitamins, helping more people get access. No extra safety worries or delays—just a green light for more affordable options soon!

## Abstract

The Food and Drug Administration (FDA, Agency, or we) has determined that M.V.I. ADULT (ascorbic acid 200 milligrams (mg)/vial; biotin 0.06 mg/vial; cyanocobalamin 0.005 mg/vial; dexpanthenol 15 mg/ vial; ergocalciferol 0.005 mg/vial; folic acid 0.6 mg/vial; niacinamide 40 mg/vial; pyridoxine hydrochloride 6 mg/vial; riboflavin 5'-phosphate sodium 3.6 mg/vial; thiamine hydrochloride 6 mg/vial; vitamin A 1 mg/ vial; vitamin E 10 mg/vial; vitamin K 0.15 mg/vial), for injection, was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for ascorbic acid 200 mg/vial; biotin 0.06 mg/ vial; cyanocobalamin 0.005 mg/vial; dexpanthenol 15 mg/vial; ergocalciferol 0.005 mg/vial; folic acid 0.6 mg/vial; niacinamide 40 mg/vial; pyridoxine hydrochloride 6 mg/vial; riboflavin 5'-phosphate sodium 3.6 mg/vial; thiamine hydrochloride 6 mg/vial; vitamin A 1 mg/ vial; vitamin E 10 mg/vial; vitamin K 0.15 mg/vial, for injection, if all other legal and regulatory requirements are met.

## Effects PRIA read

- Green light to seek generics for M.V.I. ADULT: benefit, low. The FDA determined that M.V.I. ADULT (NDA 021625, initially approved January 30, 2004), a multivitamin injection indicated for prevention of vitamin deficiency in adults and pediatric patients aged 11 years and above receiving parenteral nutrition, was not withdrawn for reasons of safety or effecti…
- Possible labeling updates requested for ANDA applicants: cost, low. The notice says that if FDA determines the labeling for M.V.I. ADULT should be revised to meet current standards, the Agency will advise ANDA applicants to submit such updated labeling. ANDA applicants that pursue approval for this product should be prepared to provide labeling conforming to any FD…

## Related documents

- [2026-23351](https://policyrisk.com/federal-register/2026-23351): Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition, 2026-11-17
- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25

## Sources
- [2026-23366 on federalregister.gov](https://www.federalregister.gov/documents/2026/11/17/2026-23366/determination-that-mvi-adult-multiple-vitamins-for-injection-was-not-withdrawn-from-sale-for-reasons)
- [2026-23366 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-11-17/pdf/2026-23366.pdf)

## Related
- [Previous: 2026-23362, Combined Notice of Filings](https://policyrisk.com/federal-register/2026-23362)
- [Next: 2026-23367, Determination That M.V.I. PEDIATRIC (Multiple Vitamins for Injection) Was Not W…](https://policyrisk.com/federal-register/2026-23367)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-23366 (as of 2026-11-17).
